Table 2.

Outcomes comparing severe cases and non-severe cases of COVID-19.

Outcomes	Critical illness				Non-critical illness
	No. reports	No. patients	Prevalence% (95%CI)	I2 (%)	No. reports	No. patients	Prevalence% (95%CI)	I2 (%)
Clinical symptoms
Fever	6	364	80.8 (41.1–100.0)	97	6	1299	71.2 (23.8–99.9)	98
Cough	6	364	65.6 (51.7–78.2)	67	6	1299	56.7 (39.5–73.2)	88
Sore throat	3	245	16.7 (0.0–53.2)	77	3	1135	11.2 (3.5–22.4)	63
Increased sputum production	3	222	32.1 (15.6–51.0)	19	3	1065	31.4 (23.1–40.5)	14
Shortness of breath	6	364	49.2 (21.5–77.2)	90	5	1216	13.3 (2.2–30.9)	85
Myalgia	5	351	17.6 (8.2–29.5)	57	5	1201	20.8 (10.0–33.9)	85
Fatigue	4	299	41.2 (5.2–84.0)	92	5	1201	34.5 (13.2–59.6)	93
Diarrhea	4	234	7.6 (0.0–24.0)	55	3	1053	4.3 (0.1–12.5)	54
Headache	4	274	11.3 (0.1–33.9)	74	5	1172	11.9 (5.8–19.7)	53
Laboratory findings
Leucocytes (↑)	2	186	27.7 (0.0–100.0)	91	3	838	9.3 (0.0–1.0)	67
Leucocytes (↓)	3	216	33.7 (0.00–95.7)	92	3	957	27.2 (24.3–30.1)	0
Lymphocytes (↓)	3	203	81.5 (18.9–100.0)	94	4	883	59.6 (32.2–84.2)	99
Platelets (↓)	2	169	32.3 (0.0–100.0)	93	3	740	16.4 (0.0–1.0)	88
Aspartate aminotransferase (↑)	2	155	46.1 (0.0–100.0)	56	3	653	15.5 (0.0–50.8)	55
Creatinine (↑)	2	151	6.4 (0.0, 100.0)	57	2	642	2.3 (0.0, 97.1)	76
Creatine kinase (↑)	2	134	28.6 (0.0–100.0)	76	3	563	16.7 (0.0–1.0)	96
Lactate dehydrogenase (↑)	3	173	62.7 (55.7–100.0)	83	3	818	28.1 (0.0, 100.0)	99
C-reactive protein (↑)	2	171	40.3 (0.0–100.0)	99	5	1026	51.2 (38.6–63.8)	71
D-dimer (↑)	2	109	59.6 (50.2–68.7)	0	1	451	43.2 (38.7–47.8)	0
Procalcitonin (↑)	3	165	35.7 (0.0–100.0)	95	4	660	55.2 (0.0–33.8)	95
Chest CT findings
Bilateral pneumonia	2	186	91.0 (0.0–100)	83	1	926	39.7 (36.6–42.9)	0
Complications
ARDS	4	315	38.2 (3.2–83.0)	96	2	130	4.3 (2.8, 6.0)	0
Cardiac failure	4	155	17.1 (1.5–42.2)	78	2	130	1.9 (0.0, 26.0)	0
Shock	3	222	17.4 (0.0, 61.5)	87	.	.	.	.
Renal insufficiency	5	328	9.8 (0.1–28.7)	87	.	.	.	.

ARDS=Acute Respiratory Distress Syndrome.